Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Accounts Payables (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Accounts Payables for 12 consecutive years, with $10.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 26.62% to $10.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.8 million, a 26.62% increase, with the full-year FY2025 number at $10.8 million, up 26.62% from a year prior.
  • Accounts Payables was $10.8 million for Q4 2025 at Niagen Bioscience, down from $12.7 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $13.7 million in Q2 2025 to a low of $6.9 million in Q3 2024.
  • A 5-year average of $9.9 million and a median of $10.0 million in 2021 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: fell 24.95% in 2024, then surged 84.59% in 2025.
  • Niagen Bioscience's Accounts Payables stood at $10.4 million in 2021, then dropped by 7.14% to $9.7 million in 2022, then rose by 5.71% to $10.2 million in 2023, then fell by 16.67% to $8.5 million in 2024, then increased by 26.62% to $10.8 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Accounts Payables are $10.8 million (Q4 2025), $12.7 million (Q3 2025), and $13.7 million (Q2 2025).